Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights • COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025 • Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD) • Michael Gold to join Compass as Head of R&D • Compass enters into additional commercial collaborations, including with Reliant Medical Group, part ...